Article Text

Download PDFPDF

PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment
  1. Giulia Buonaiuto1,
  2. Valentina De Mori1,
  3. Alessandra Braus2,
  4. Annalisa Balini1,
  5. Denise Berzi1,
  6. Rita Carpinteri1,
  7. Franco Forloni1,
  8. Giancarla Meregalli1,
  9. Gian Luca Ronco3,
  10. Antonio C Bossi1
  1. 1Endocrine Unit, Diabetes Regional Center, Treviglio, Italy
  2. 2Pharmacy Unit, ASST Bergamo Ovest (Bg), Treviglio, Italy
  3. 3Emmonos, IT HealthCare Senior Consultant, Como, Italy
  1. Correspondence to Dr Antonio C Bossi; antonio_bossi{at}asst-bgovest.it

Abstract

Objectives The UK Prospective Diabetes Study (UKPDS) Risk Engine (RE) provides the best risk estimates available for people with type 2 diabetes (T2D), so it was applied to patients on persistent sitagliptin treatment.

Design A ‘real-world’ retrospective, observational, single-center study.

Setting The study was performed in a general hospital in Northern Italy in order: (1) to validate UKPDS RE in a cohort of Italian participants with T2D without prespecified diabetes duration, with/without cardiovascular (CV) disease, treated with sitagliptin; (2) to confirm CV risk gender difference; (3) to evaluate the effect on metabolic control and on CV risk evolution obtained by ‘add-on’ persistent sitagliptin treatment.

Participants Sitagliptin 100 mg once a day was taken by 462 participants with T2D: 170 of them (males: 106; age: 63.6±8.8; T2D duration: 11.58±7.33; females: 64; age: 65.6±7.95; T2D duration 13.5±7.9) were treated for 48 months with the same dosage.

Interventions An analysis of normality was performed both for continuous, and for groups variables on UKPDS RE percentage values, defining the requirement of a base log10 transformation to normalize risk factor values for analysis validation.

Results The evaluation of CV risk evolution by gender (t-test) confirmed the expected statistical difference (p<0.0001). Sitagliptin obtained significant results after 12 months, and at the end of the observation, both on metabolic control (expressed by glycated hemoglobin) and on UKPDS RE. Analysis of variance test revealed a significant effect on CV risk after 12 months (p=0.003), and after 48 months (p=0.04). A bivariate correlation analysis revealed a correlation index (r)=0.2 between the two variables (p<0.05).

Conclusions These ‘real-world’ data obtained applying UKPDS RE may reflect patients’ and clinicians’ interest in realizing individual CV risk, and its evolution. Sitagliptin-persistent treatment for a medium–long period obtained an improvement on metabolic control, as well as a reduction on CV risk.

  • Incretin
  • Cardiovascular Risk Assessment
  • Glucose Control
  • Gender Differences

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.